Scarica l'app Stockscreener
1.26
0.00%
0.00
Dopo l'orario di chiusura:
1.25
-0.01
-0.79%
An 2 Therapeutics Inc Borsa (ANTX) Ultime notizie
Cognition Therapeutics, Inc. Achieves 75% Enrollment in Phase 2 START Study for Early Alzheimer’s Disease Treatment - Quiver Quantitative
Hoth Therapeutics Inc. Eyes Future Growth Amidst Current Market Dynamics - StocksToTrade
Levi & Korsinsky Notifies Shareholders of Capricor Therapeutics, Inc.(CAPR) of a Class Action Lawsuit and an Upcoming Deadline - Morningstar
United Therapeutics Corporation announces Teton-2 pivotal study of Tyvaso meets primary endpoint for the treatment of idiopathic pulmonary fibrosis - MarketScreener
95.6mL Lung Function Improvement: United Therapeutics' Tyvaso Achieves Breakthrough in IPF Treatment Trial - Stock Titan
Relmada Therapeutics, Inc. (RLMD) Reports 91% Response Rate in Phase 2 Bladder Cancer Study - Yahoo Finance
Serina Therapeutics Announces FDA Feedback Supports - GlobeNewswire
Novel Brain Hormone Therapy PT00114 Targets Stress Response: Protagenic's Phase 1 Trial Advances - Stock Titan
Mountain Crest Acquisition Corp. II/Better Therapeutics, Inc. Class Action – Important Settlement Information - Business Wire
Viking Therapeutics: Phase 2 Oral Obesity Data Affirms Bear Case, Downgrade To Sell (VKTX) - Seeking Alpha
Viking Therapeutics Reports Positive Phase 2 Trial Results - TipRanks
Viking Therapeutics Announces Positive Top-Line Results from Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity - PR Newswire
Capricor Therapeutics, Inc. Sued for Securities Law ViolationsInvestors Should Contact Levi & Korsinsky for More InformationCAPR - The Malaysian Reserve
Plus Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Xilio Therapeutics shares fall 2.52% intraday after announcing updated Phase 2 data for vilastobart. - AInvest
Nanoscope Therapeutics Announces Publication of STARLIGHT Phase 2 Study Evaluating MCO-010 Gene-Agnostic Therapy in Patients with Stargardt Disease - PR Newswire
Candel Therapeutics, Inc. SEC 10-Q Report - TradingView
BRAINSTORM CELL THERAPEUTICS INC. SEC 10-Q Report - TradingView
Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2025 Financial Results - Yahoo Finance
Werewolf Therapeutics, Inc. SEC 10-Q Report - TradingView
Allogene Therapeutics, Inc. SEC 10-Q Report - TradingView
Allogene Therapeutics Advances Pivotal Phase 2 ALPHA3 Trial for Cema-Cel in Large B-Cell Lymphoma and Initiates Phase 1 Trials for Autoimmune Disease and Renal Cell Carcinoma - Quiver Quantitative
Compass Therapeutics And 2 Other Promising Penny Stocks To Consider - simplywall.st
Cognition Therapeutics Receives End-of-Phase 2 Meeting - GlobeNewswire
Breakthrough Alzheimer's Drug Zervimesine Advances to Phase 3 with Novel Blood Test Strategy - Stock Titan
BridgeBio Oncology Therapeutics, Inc. Completes Business Combination with Helix Acquisition Corp. II, Secures $382 Million in Gross Proceeds - Quiver Quantitative
Tenaya Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update - Yahoo Finance
Cardiol Therapeutics Announces Topline Results from the Phase II ARCHER Trial of CardiolRx(TM) in Acute Myocarditis - Newsfile
Windtree Therapeutics, Inc. Reports Positive Interim Analysis for Istaroxime in Phase 2 Study of Cardiogenic Shock - Quiver Quantitative
BioXcel Therapeutics Completes Phase 3 Trial, Awaits FDA Decision - StocksToTrade
Apogee Therapeutics, Inc. (APGE) Soars on Promising Phase 2 Results for Atopic Dermatitis Drug - MSN
BioXcel Therapeutics Announces Last Patient Last Visit in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia - GlobeNewswire
United Therapeutics Corporation Reports Record Second Quarter 2025 Financial Results - Business Wire
Sangamo Therapeutics Announces Positive Phase 1/2 STAAR Study Results for Fabry Gene Therapy - Yahoo Finance
Cardiol Therapeutics Announces Database Lock for Phase II ARCHER Trial of CardiolRx(TM) in Acute Myocarditis - Newsfile
DiaMedica Therapeutics Reports Positive Interim Phase 2 Preeclampsia Results: Statistically Significant Reductions in Blood Pressure and No Placental Transfer - Yahoo Finance
Cognition Therapeutics, Inc. Reports Promising Results for Zervimesine in Phase 2 Alzheimer’s and Dementia with Lewy Bodies Studies - Nasdaq
Cognition Therapeutics' Positive Clinical Data from Zervimesine (CT1812) Phase 2 Study in Dementia with Lewy Bodies (DLB) will be Presented in a Podium Presentation at AAIC - GlobeNewswire
Compass Therapeutics And 2 Other Promising Penny Stocks To Watch - Yahoo Finance
Ovid Therapeutics (NASDAQ:OVID) Stock Price Down 2% – Time to Sell? - Defense World
Allogene Therapeutics And 2 Other Promising Penny Stocks To Watch - Yahoo Finance
Cognition Therapeutics, Inc. (CGTX) Retains Buy Rating on START Study Progress - Yahoo Finance
Cognition Therapeutics, Inc. Discusses Phase 2 Results and Future Plans for Zervimesine Treatment in Alzheimer's Disease with FDA - Nasdaq
Cognition Therapeutics Completes End-of-Phase 2 Meeting with FDA for Zervimesine (CT1812) in Alzheimer’s Disease - GlobeNewswire
Breakthrough for Alzheimer's Treatment: FDA Meeting Clears Path for Zervimesine Phase 3 Program - Stock Titan
First Patient Dosed in XyloCor Therapeutics’ Phase 2b EXACT-2 Trial Evaluating XC001 for the Treatment of Coronary Artery Disease - Business Wire
Rhythm Pharmaceuticals Announces Oral MC4R Agonist Bivamelagon Achieved Statistically Significant, Clinically Meaningful BMI Reductions in Placebo-controlled Phase 2 Trial in Acquired Hypothalamic Obesity - Yahoo Finance
Unicycive Therapeutics (NASDAQ:UNCY) Trading 2% Higher – Time to Buy? - Defense World
Avenzo Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Study of AVZO-1418, a Potential Best-in-Class EGFR/HER3 Bispecific Antibody-Drug Conjugate - Business Wire
Apogee Therapeutics Announces Positive 16-Week Data from - GlobeNewswire
New Atopic Dermatitis Drug Shows Record-Breaking 67% Success Rate, Could Reduce Injections to Just 4 Times Per Year - Stock Titan
Apogee Therapeutics to Host Conference Call to Report Part A 16-Week Data from the Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis on July 7, 2025 - GlobeNewswire
Cognition Therapeutics Shares Jump 12% After Hours Following Encouraging Phase 2 Alzheimer's Trial Data - Benzinga
Alembic Pharmaceuticals up 2% as arm acquires Utility Therapeutics; details - Business Standard
Ligand Announces Completion of Pelthos Therapeutics Merger with Channel Therapeutics - Yahoo Finance
Cognition Therapeutics Reports Over 50% Enrollment in Phase 2 START Study for Alzheimer's Treatment - Nasdaq
Arcturus Therapeutics Announces Positive Interim Phase 2 Multiple Dose Data for Ornithine Transcarbamylase (OTC) Deficiency Program - biospace.com
Tango Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of TNG462 plus Revolution Medicines’ Daraxonrasib or Zoldonrasib in Patients with RAS-Mutant MTAP-deleted Pancreatic or Lung Cancer - GlobeNewswire
Cognition Therapeutics Provides Regulatory Update on Zervimesine (CT1812) in Alzheimer’s Disease and Dementia with Lewy Bodies (DLB) - GlobeNewswire
Sangamo Therapeutics Announces Positive Topline Results From Registrational STAAR Study in Fabry Disease - Business Wire
Cidara Therapeutics Announces Positive Topline Results from - GlobeNewswire
Capricor Therapeutics Announces Positive 4-Year Data from HOPE-2 Open-Label Extension Study of Deramiocel in Duchenne Muscular Dystrophy - Yahoo Finance
$452M Deal: Processa's Phase 2 Gastroparesis Drug Shows Promise, Attracts Major Licensing Interest - Stock Titan
Glenmark Therapeutics Inc., USA launches Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% (OTC) - PR Newswire
Celldex Presents Data Demonstrating Profound Long Term Improvement in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2025 - GlobeNewswire
Layoff Tracker: ADC Therapeutics Cutting 30% of Staff, Closing London Research Facility - BioSpace
Beam Therapeutics Announces New Data from BEACON Phase 1/2 - GlobeNewswire
1.40%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):